Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared on LinkedIn about a recent paper by Matthew Vogel et al. published on JCO:
“ADCs are not just “guided missiles” – new biology is reshaping how we view them
Continuous payload exposure in circulation sustains cytotoxic thresholds
Antigen level ≠ response: extracellular cleavage enables efficacy in ‘HER2-zero’ tumors
Fc functions and TME interactions may shape efficacy and toxicity (e.g., ILD, thrombocytopenia)
Cross-resistance across TOP1i ADCs → need for payload diversification
Future: dual-payload ADCs, tumor-selective linkers, ADC–ICI combinations?”
Title: Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
Authors: Matthew Vogel, Raffaele Colombo, and Paolo Tarantino
More insights from Jean-Charles Soria.